Login
Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

mirumpharma.com

What Do They Do?

Sells medicines for rare liver diseases and other rare disorders to pharmacies and distribution partners.

How Do They Make Money?

Pharmacies and distribution partners pay for approved medicines when the products are delivered. License and collaboration arrangements can also bring upfront fees, milestone payments and royalties tied to product sales.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Total product sales, net
Sold outright

100%
FY2022: 97%
License and other revenue
Licensed
0.0%
FY2022: 2.6%

Who Are Their Customers?

In the U.S. and Canada, specialty pharmacies distribute its medicines; elsewhere, pharmacies receive them through logistics providers, authorized distributors or licensed partners. Governments place periodic orders in some countries.

Do Revenues Turn Into Profits?

Not on paper. It lost $23.4M in FY2025, but brought in more cash than it spent: $54.9M of free cash flow.

Operating income, FY2025
−4% of revenue
▲ +75% (Loss) vs FY2024 (−$87.6M, −26%)
Net income, FY2025
−4% of revenue
▲ +73% (Loss) vs FY2024 (−$87.9M, −26%)
Free cash flow, FY2025
11% of revenue
▲ +488% vs FY2024 ($9.3M, 3%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +40%
vs $133M in Q3 FY2025
Net income
▼ Turned to a loss
vs $2.9M in Q3 FY2025
Product sales, net share of revenue vs 100.0% in Q3 FY2025
  • Sep 25, 2026 FDA approves Atebrioz for FOP The medicine is licensed to Mirum for worldwide development and commercialization.

Growing. Revenue grew 27.2x in 4 years, from $19.1M in FY2021 to $521.3M in FY2025, about 128% a year.

Broader commercial portfolio The older report described Livmarli as its commercial product and volixibat as a candidate; the latest report also describes Cholbam and Ctexli as marketed medicines.

Livmarli’s PFIC status The older report described Livmarli as approved for ALGS and under development for PFIC; the latest report describes it as approved for PFIC in several markets.

Revenue over time
Total product sales, net License and other revenue License
$1B$500M$0

Who Do They Compete With?

Competes with GSK, Ipsen Pharma, Alfasigma, Gilead Sciences, Vir Biotechnology, Shionogi &, Harmony Biosciences, Dr. Falk Pharma, Leadiant Biosciences, Laboratoires CTRS, Zydus Therapeutics, Calliditas Therapeutics, NGM Biopharmaceuticals, Chemomab Therapeutics, and Pliant Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support